Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

KORU Medical Systems (KRMD) Research & Development (2020 - 2025)

Historic Research & Development for KORU Medical Systems (KRMD) over the last 11 years, with Q3 2025 value amounting to $933107.0.

  • KORU Medical Systems' Research & Development fell 3916.55% to $933107.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 1978.49%. This contributed to the annual value of $5.3 million for FY2024, which is 843.42% down from last year.
  • KORU Medical Systems' Research & Development amounted to $933107.0 in Q3 2025, which was down 3916.55% from $1.2 million recorded in Q2 2025.
  • KORU Medical Systems' 5-year Research & Development high stood at $1.6 million for Q4 2022, and its period low was $336841.0 during Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $1.1 million (2022), whereas its average is $1.1 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 24091.9% in 2022, then plummeted by 3916.55% in 2025.
  • Over the past 5 years, KORU Medical Systems' Research & Development (Quarter) stood at $949930.0 in 2021, then soared by 72.85% to $1.6 million in 2022, then dropped by 21.59% to $1.3 million in 2023, then fell by 13.46% to $1.1 million in 2024, then dropped by 16.25% to $933107.0 in 2025.
  • Its last three reported values are $933107.0 in Q3 2025, $1.2 million for Q2 2025, and $1.1 million during Q1 2025.